Differential Expression of Enhancer of Zeste Homolog 2 (EZH2) Protein and Intracellular Signaling Molecules p-ERK, MYC, and p-STAT3 in Low and High Grade B-Cell Non-Hodgkin Lymphomas

被引：0
|
作者：
Tian, Xuejun [1 ]
Shahsafaei, Ali [1 ]
Dolfman, David M. [1 ]
机构：
[1] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA
来源：
MODERN PATHOLOGY | 2016年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
1493
引用
收藏
页码：379A / 379A
页数：1
相关论文
共 30 条
  • [21] Differential Eμ enhancer activity and expression of BOB.1/OBF.1, Oct2, PU.1, and immunoglobulin in reactive B-cell populations, B-cell non-Hodgkin lymphomas, and Hodgkin lymphomas
    Loddenkemper, C
    Anagnostopoulos, L
    Hummel, M
    Johrens-Leder, K
    Foss, HD
    Jundt, F
    Wirth, T
    Dörken, B
    Stein, H
    JOURNAL OF PATHOLOGY, 2004, 202 (01): : 60 - 69
  • [22] A Phase I Study of GSK2816126, an Enhancer of Zeste Homolog 2(EZH2) Inhibitor, in Patients (pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Other Non-Hodgkin Lymphomas (NHL), Transformed Follicular Lymphoma (tFL), Solid Tumors and Multiple Myeloma (MM)
    Yap, Timothy A.
    Winter, Jane N.
    Leonard, John P.
    Ribrag, Vincent
    Constantinidou, Anastasia
    Giulino-Roth, Lisa
    Michot, Jean-Marie
    Khan, Tariq A.
    Horner, Thierry
    Carver, Jennifer
    Dumetrescu, Teodora Pene
    He, Zangdong
    McCabe, Michael T.
    Creasy, Caretha L.
    Dhar, Arindam
    Carpenter, Christopher
    Johnson, Peter M.
    BLOOD, 2016, 128 (22)
  • [23] EZH2 and CD79B Mutational Status Over Time in B-Cell Non-Hodgkin Lymphomas Detected by High-Throughput Sequencing Using Minimal Samples
    Saieg, Mauro Ajaj
    Geddie, William R.
    Boerner, Scott L.
    Bailey, Denis
    Crump, Michael
    Santos, Gilda da Cunha
    CANCER CYTOPATHOLOGY, 2013, 121 (07) : 377 - 386
  • [24] P27Kip1 immunostaining is a useful marker for the differential diagnosis of low grade B-cell non-Hodgkin lymphomas (NHL) in bone marrow (BM) biopsies.
    Kremer, M
    Dimhofer, S
    Quintanilla-Martinez, L
    Fend, F
    MODERN PATHOLOGY, 2001, 14 (01) : 169A - 169A
  • [25] P27Kip1 immunostaining is a useful marker for the differential diagnosis of low grade B-cell non-Hodgkin lymphomas (NHL) in bone marrow (BM) biopsies.
    Kremer, M
    Dimhofer, S
    Quintanilla-Martinez, L
    Fend, F
    LABORATORY INVESTIGATION, 2001, 81 (01) : 169A - 169A
  • [26] Translocation (2;7)(p11.2;q22) in a newly diagnosed low-grade B-cell non-Hodgkin lymphoma
    Ambika, Santhosh
    Oo, Thein Hlaing
    CANCER GENETICS AND CYTOGENETICS, 2008, 181 (01) : 65 - 66
  • [27] A phase I, open-label study of GSK2816126, an enhancer of zeste homolog 2 (EZH2) inhibitor, in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (tFL), other non-Hodgkin's lymphomas (NHL), multiple myeloma (MM) and solid tumor.
    Yap, Timothy Anthony
    Johnson, Peter W. M.
    Winter, Jane
    Leonard, John
    Giulino-Roth, Lisa
    Horner, Thierry
    Radswillas, Kristen
    Carver, Jennifer
    Dhar, Arindam
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [28] Frequent allelic losses of 9p21 markers and low incidence of mutations at p16(CDKN2) gene in non-Hodgkin lymphomas of B-cell lineage
    FernandezPiqueras, J
    Santos, J
    Perez de Castro, I
    Melendez, B
    Martinez, B
    Robledo, M
    Rivas, C
    Benitez, J
    CANCER GENETICS AND CYTOGENETICS, 1997, 98 (01) : 63 - 68
  • [29] High-grade malignant non-Hodgkin's lymphomas differ from low-grade lymphomas in the extent of apoptosis and their expression of bcl-2, mcl-1, bax and p53
    Soini, Y
    Raunio, H
    Pääkkö, P
    TUMOR BIOLOGY, 1998, 19 (03) : 176 - 185
  • [30] Detection of single and associated lesions of the Bcl-1, Bcl-2, Bcl-6, c-myc, p53 and p16 genes in B-cell non-Hodgkin's lymphomas:: value of molecular analysis for a better assignment of the histologic subtype
    García-Sanz, R
    Montero, MV
    Díaz, MG
    del Carmen, M
    Santos, C
    Echevarria, AB
    Corral, TF
    Martin, JMH
    Barrigón, MDC
    San Miguel, JF
    HAEMATOLOGICA, 1998, 83 (03) : 209 - 216
123